Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$27.93 USD
+1.17 (4.38%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $27.92 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ARCT 27.93 +1.17(4.38%)
Will ARCT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARCT
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
Other News for ARCT
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Analysts’ Top Healthcare Picks: Elevance Health (ELV), Argenx Se (ARGX)
As more rare disease therapies launch, their prices are rising
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline Progress